Amgen falls after obesity study results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Amgen (AMGN) PT Raised to $352 at Leerink Partners
November 27, 2024 6:19 AM ESTLeerink Partners analyst David Risinger raised the price target on Amgen (NASDAQ: AMGN) to $352.00 (from $305.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are lowering our PT from $352 (18x 2025E EPS of $19.55) to $305 (15x 2025E EPS of $20.33) and maintaining our Market Perform rating. We lowered our 5- yr (25-30) CAGR EPS from 8% to 4%, largely driven by higher investment spending assumptions. MariTides Ph2 results... More
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
November 26, 2024 10:37 AM ESTPiper Sandler analyst Christopher Raymond reiterated an Overweight rating and $344.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Remain OW rated on AMGN shares and would expect the stock to eventually recover from todays initial sell-off on AMGNs... More
